Planning Committee named for the Third International Summit on Human Genome Editing

Update: Third International Summit on Human Genome Editing postponed to 2023

The UK Royal Society, Academy of Medical Sciences, the US National Academies of Sciences and Medicine and UNESCO-The World Academy of Sciences for the advancement of science in developing countries (TWAS) are jointly organising the Third International Summit on Human Genome Editing in March 2023.

The in-person event (with an option to attend online) will take place in at the Francis Crick Institute in London over three days from March 6th – 8th, 2023.

A multidisciplinary planning committee comprising representatives from eleven nations has been appointed to plan the summit, which is being chaired by Professor Robin Lovell-Badge FMedSci FRS. We are pleased to announce that Dr. Daria Julkowska, Coordinator of the EJP RD, is a member of the planning committee.

A statement issued by the Presidents of the partner academies emphasises that the 2022 Summit will build on previous events held in Washington, D.C. (2015), and Hong Kong (2018) and inform and catalyse debate around current and potential uses of genome editing technologies in humans by bringing together speakers and participants from a broader range of countries. The Summit will also provide an opportunity to discuss and explore the findings and recommendations of the 2020 report of the International Commission on the Clinical Use of Human Germline Genome Editing and the 2021 reports by the World Health Organization’s Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing.

During the Summit, international stakeholders representing the academic, medical, regulatory, bioethical, and patient communities will discuss global considerations regarding human genome editing, including:

  • An update on advances in science and techniques in non-heritable and epigenetic genome editing since the 2018 Summit
  • Current clinical research involving non-heritable genome editing and barriers to clinical applications
  • The state of the science for germline genome editing in embryos and gametes
  • Policy approaches to increase capacity and accessibility to treatments for genetic diseases globally
  • Discussion of recent reports from the World Health Organization and potential methods for developing international and national regulatory frameworks
  • Ethical, societal and cultural considerations surrounding human genome editing
  • The role of non-scientists, including the public, in setting the research agenda.

For more information: